Core Viewpoint - A class action lawsuit has been filed against ChowChow Cloud International Holdings Limited (CHOW) for securities fraud, affecting shareholders who acquired CHOW securities between September 16, 2025, and December 10, 2025 [1][2]. Summary by Relevant Sections Company Background - ChowChow Cloud International Holdings Limited conducted its initial public offering (IPO) on September 16, 2025, selling 2.6 million ordinary shares at $4.00 per share [3]. Incident Overview - Following the IPO, CHOW experienced significant price and volume increases without any relevant news or filings, indicating potential market manipulation [3]. - On December 10, 2025, the manipulation scheme was exposed, leading to trading halts due to volatility, and CHOW's stock price plummeted by $9.87, or 84.3%, closing at $1.83 per share [4]. Lawsuit Details - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements and failed to disclose critical adverse facts about the company's operations and risks [5]. - Specific allegations include the failure to disclose that CHOW was subject to a market manipulation scheme, the omission of risks related to fraudulent trading, and misleading positive statements about the company's business [6].

Core Viewpoint - Soleno Therapeutics, Inc. is facing a securities fraud lawsuit due to allegations of misleading statements and undisclosed risks related to its drug DCCR, which has resulted in significant stock price declines and investor losses [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2026, with a deadline to file a lead plaintiff motion by May 5, 2026 [1][7]. - The lawsuit alleges that Soleno made materially false and misleading statements regarding the safety and efficacy of DCCR, particularly concerning serious adverse reactions reported by patients [5][6]. Group 2: Stock Price Impact - Following the release of a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell by $9.27 per share, or 11.98%, closing at $68.09 on August 18, 2025 [3]. - After a patient death was disclosed on September 10, 2025, the stock price dropped by $13.49 per share, or 19.21%, closing at $56.72 on September 11, 2025 [3]. - On November 4, 2025, Soleno reported financial results indicating that the negative report had disrupted DCCR's launch, leading to a further decline of $16.98 per share, or 26.59%, closing at $46.87 on November 5, 2025 [4][5]. Group 3: Allegations Against Soleno - The lawsuit claims that Soleno's Phase 3 clinical trial for DCCR downplayed significant safety concerns, including issues related to excess fluid retention [6]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and increased patient discontinuation rates [6].

Law Offices of Frank R. Cruz Encourages Driven Brands Holdings Inc. (DRVN) Shareholders To Inquire About Securities Fraud Class Action Mar 16, 2026 12:07 PM Eastern Daylight Time IF YOU SUFFERED A LOSS ON YOUR DRIVEN BRANDS HOLDINGS INC. (DRVN) INVESTMENTS, CLICK HERETO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, ...

Core Viewpoint - Horizon Technology Finance Corporation is under investigation for potential violations of securities laws, specifically regarding misleading statements and undisclosed information that may have affected investors [1]. Financial Performance - Horizon reported a significant decrease in investment income for Q4 and the full year 2025, attributing this decline to lower prepayment activity during the quarter [1]. - The company also experienced a decline in net asset value per share compared to the previous quarter [1]. - Following the release of these financial results, shares of Horizon fell by 23.3% the next day [1]. Legal Context - The Schall Law Firm is leading the investigation and is encouraging affected shareholders to participate and discuss their rights [1]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, indicating a focus on protecting investor interests [1].

Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against Disc Medicine, Inc. (NASDAQ: IRON) related to violations of securities laws, particularly concerning misleading statements and undisclosed information impacting investors [1]. Group 1: Company Overview - Disc Medicine, Inc. is currently facing scrutiny due to a delay in the review timeline of its experimental drug, which was flagged by U.S. FDA scientists for safety and efficacy concerns [1]. - Following the news of the FDA's concerns, shares of Disc Medicine fell by more than 7.8% on the same day [1]. Group 2: Legal Investigation - The Schall Law Firm is encouraging shareholders who have suffered losses to participate in the investigation and to contact them for a free discussion of their rights [1]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [1].

Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against Planet Fitness, Inc. for possible violations of securities laws, particularly regarding misleading statements and undisclosed information [1] Financial Performance - Planet Fitness announced its Q4 and full year 2025 financial results on February 24, 2026, projecting a revenue increase of 9% for the next year, which was below analyst estimates and the company's own three-year projection [1] - Following the announcement, shares of Planet Fitness dropped by nearly 9% on the same day [1]

Core Viewpoint - Driven Brands Holdings Inc. (DRVN) is facing a class action lawsuit due to significant errors in its financial statements, which led to a substantial drop in stock price and investor losses [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Driven Brands common stock between May 9, 2023, and February 24, 2026, with a deadline to file a lead plaintiff motion by May 8, 2026 [1] - The lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and operations [1] - Specific errors identified include inappropriate revenue recognition, unreconciled cash account differences, and overstatements of expenses, among others [1] Group 2: Financial Impact - Following the disclosure of financial errors on February 25, 2025, Driven Brands' stock price fell by $5.01, or 30.2%, closing at $11.60 per share [1] - The company indicated that it may identify further material errors in its financial statements, which could lead to additional financial restatements [1] Group 3: Investor Actions - Investors who suffered losses are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights and potentially participate in the class action [1] - The law firm provides contact information for investors to inquire about their rights and the ongoing lawsuit [1]

Core View - Trip.com Group Limited is facing a securities fraud class action lawsuit due to allegations of failing to disclose material information during the class period from April 30, 2024, to January 13, 2026 [1] - The company is under investigation by the State Administration for Market Regulations of China for alleged monopolistic practices, which has led to a significant decline in its stock price [1] Legal Proceedings - Investors have until May 11, 2026, to file lead plaintiff applications in the class action lawsuit against Trip.com [1] - The lawsuit claims that Trip.com and its executives violated federal securities laws by not disclosing critical information [1] Stock Performance - Following the news of the antitrust probe, Trip.com’s American Depositary Shares (ADS) dropped by $12.90, or 17.05%, closing at $62.78 on January 14, 2026 [1] - The stock continued to decline, falling an additional $1.48, or 2.35%, to close at $61.30 on January 15, 2026 [1]

Core Viewpoint - Boston Scientific Corporation (BSX) is facing a securities fraud class action lawsuit due to disappointing financial results and misleading statements regarding its U.S. Electrophysiology (EP) segment growth [1] Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 results, highlighting a shortfall in U.S. Electrophysiology sales and issuing fiscal 2026 guidance that fell below market expectations [1] - The company's stock price dropped by $16.12, or 17.6%, closing at $75.50 per share following the announcement [1] Class Action Details - The class action lawsuit is on behalf of investors who acquired Boston Scientific securities between July 23, 2025, and February 3, 2026 [1] - The lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and growth prospects [1] Allegations Against the Company - The complaint claims that Boston Scientific's U.S. EP segment growth rate was unsustainable and that new competition was negatively impacting its market share [1] - It is alleged that the company's previous statements of confidence regarding the EP division's growth trajectory were materially misleading [1]

Core Insights - Blackstone Trial Group has launched as a specialized litigation firm focused exclusively on defending correctional healthcare providers against medical malpractice and civil rights claims [1] - The firm aims to address the unique challenges faced by healthcare professionals in correctional settings, ensuring fair representation and outcomes in legal matters [1] Group 1: Company Overview - Blackstone Trial Group, PLLC is headquartered in Birmingham, Alabama, and Dallas, Texas, and serves clients nationwide [1] - The firm was founded by Susanne Moore, who has extensive experience in both healthcare and legal fields, providing a unique understanding of the complexities in correctional healthcare [1][1] - The firm operates without a traditional billable hour model, focusing instead on efficiency and results [1] Group 2: Services Offered - The firm provides comprehensive litigation services, including defense against medical malpractice claims, Section 1983 civil rights litigation, wrongful death actions, and deliberate indifference claims under the Eighth Amendment [1] - Blackstone Trial Group represents individual healthcare professionals, correctional healthcare companies, and institutions, with trial attorneys prepared to take cases through verdict [1] Group 3: Industry Context - Correctional healthcare is characterized by significant challenges, including security protocols, resource limitations, and a patient population with high rates of chronic illness and mental health conditions [1] - The firm emphasizes the importance of understanding the operational challenges faced by correctional healthcare providers, which informs their legal strategies [1]